Skip Navigation
Skip to contents



10 results

Characterization of RhoA-mediated Chemoresistance in Gastric Cancer Cells

Kang WK, Lee I, Park C

  • Cancer Res Treat.
  • 2005 Aug;37(4):251-256.
PURPOSE: RhoA is a critical transducer of extracellular signals, which leads to organization of actin cytoskeleton, motility, adhesion and gene regulation. The present study aimed to explore whether RhoA influences...
The Relationship between Expression of the Sodium/iodide Symporter Gene and the Status of Hormonal Receptors in Human Breast Cancer Tissue

Oh HJ, Chung JK, Kang JH, Kang WJ, Noh DY, Park IA, Jeong JM, Lee DS, Lee MC

  • Cancer Res Treat.
  • 2005 Aug;37(4):247-250.
PURPOSE: It has been reported that the sodium/iodide symporter (NIS) gene is expressed in several breast cancer tissues, suggesting the possibility of radionuclide imaging and therapy. However, the regulatory mechanism...
The Immunoexpressions and Prognostic Significance of Inhibin Alpha and Beta Human Chorionic Gonadotrophins (hCG) in Breast Carcinomas

Chang E, Lee E, Oh SJ, Kim JS, Kang C

  • Cancer Res Treat.
  • 2005 Aug;37(4):241-246.
PURPOSE: Pregnancy and hCG treatments are considered essential for inhibiting breast cancer. The effect of hCG is accompanied by the synthesis of inhibin, a transforming growth factor involved in cell...
Gene Promoter Hypermethylation in Tumors and Plasma of Breast Cancer Patients

Bae YK, Shim YR, Choi JH, Kim MJ, Gabrielson E, Lee SJ, Hwang TY, Shin SO

  • Cancer Res Treat.
  • 2005 Aug;37(4):233-240.
PURPOSE: To measure the hypermethylation of four genes in primary tumors and paired plasma samples to determine the feasibility of gene promoter hypermethylation markers for detecting breast cancer in the...
Expression of Maspin is associated with the Intestinal Type of Gastric Adenocarcinoma

Kim SM, Cho SJ, Jang WY, Kim DH, Shin HS, Jang MK, Kim HY, Nam ES

  • Cancer Res Treat.
  • 2005 Aug;37(4):228-232.
PURPOSE: Maspin is known as a tumor suppressor gene, but its significance has been questioned in various human cancers. The aim of this study was to investigate the expression pattern...
A Feasibility Study of Adenosine Triphosphate-based Chemotherapy Response Assay (ATP-CRA) as a Chemosensitivity Test for Lung Cancer

Kang SM, Park MS, Chang J, Kim SK, Kim H, Shin DH, Chung KY, Kim DJ, Sohn JH, Choi SH, Kim J, Yoon EJ, Kim JH

  • Cancer Res Treat.
  • 2005 Aug;37(4):223-227.
PURPOSE: A chemosensitivity test can reflect the differences in responses of individual cancer patients to chemotherapeutic agents. The adenosine triphosphate-based chemotherapy response assay (ATP-CRA)is an accurate method, which does not...
Thymidylate Synthase, Thymidine Phosphorylase, VEGF and p53 Protein Expression in Primary Colorectal Cancer for Predicting Response to 5-fluorouracil-based Chemotherapy

Ahn MJ, Choi JH, Oh HS, Lee YY, Kim IS, Choi IY, Lee KH, Song KW, Park CK

  • Cancer Res Treat.
  • 2005 Aug;37(4):216-222.
PURPOSE: In the treatment of advanced metastatic colorectal cancer, several new agents, such as irinotecan and oxaliplatin, have been developed, which have improved both disease free and overall survivals. Among...
Oxaliplatin/5-FU without Leucovorin Chemotherapy in Metastatic Colorectal Cancer

Shim BY, Lee KM, Cho HM, Kim HJ, Cho HJ, Yang J, Kim JG, Kim HK

  • Cancer Res Treat.
  • 2005 Aug;37(4):212-215.
PURPOSE: Fluorouracil (5-FU) and leucovorin combination therapy have shown synergistic or additive effect against advanced colorectal cancer, but the frequency of mucositis and diarrhea is increased. Most previous studies have...
A Phase II Trial of Haptaplatin/5-FU and Leucovorin for Advanced Stomach Cancer

Lee WS, Lee GW, Kim HW, Lee OJ, Lee YJ, Ko GH, Lee JS, Jang JS, Ha WS

  • Cancer Res Treat.
  • 2005 Aug;37(4):208-211.
PURPOSE: Heptaplatin (SKI-2053 R) is a new platinum analogue, with a better toxicity profile than cisplatin, and has antitumor activity even in cisplatin resistant cell lines. 5-fluoruracil (5-FU) has shown...
Efficacy and Safety Study of Docetaxel as Salvage Chemotherapy in Metastatic Gastric Cancer Failing Fluoropyrimidine and Platinum Combination Chemotherapy

Lee JL, Ryu MH, Chang HM, Kim TW, Yook JH, Oh ST, Kim BS, Lee JS, Kang YK

  • Cancer Res Treat.
  • 2005 Aug;37(4):201-207.
PURPOSE: Fluoropyrimidine (F) and platinum (P) combination chemotherapy has been widely used for the first line treatment of advanced gastric cancer (AGC). Docetaxel (D) has shown promising activity in this...

Go to Top

Copyright © 2020 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: